Vida Diagnostics, Inc., a Coraville, Iowa-based leader in AI-powered lung imaging analysis, received $2M from OSF Ventures, the corporate investment arm of OSF HealthCare, as a second close of its C round funding.
This investment augments an $11M investment round last month led by First Analysis Corporation.
The company intends to use the funds to further accelerate development and commercialization of its innovative solutions to impact patient care for both traditional respiratory diseases as well as emergent COVID-19 conditions.
Led by Susan A. Wood, Ph.D. and CEO, Vida provides leverages AI-powered CT imaging software and services to aid the early detection, evaluation, and treatment planning of patients with or at risk of respiratory and lung diseases, including emphysema and airway obstructive diseases (COPD), asthma, interstitial lung disease, and lung cancer. The software and services are FDA cleared, CE-marked, Health Canada licensed and TGA registered for clinical use in the US, European Economic Area, Canada and Australia.